1. Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients
- Author
-
Hatice Kilic, Emine Arguder, Aysegul Karalezli, Ebru Unsal, Rahmet Guner, Bircan Kayaslan, İmran Hasanoglu, İhsan Ates, Musa Civak, Esmehan Akpınar, Ebru Parlak, Filiz Sadi, Yasin Kocaman, Sibel Günay, Esra Metan, Mukremin Er, Aynil Dalkıran, Habibe Hezer, Hülya Ergüden, Zeynep Hancıoğlu, Ayşe Kalem, Fatma Eser, Adalet Aypak, Esragül Akıncı, Selma Karahmetoğlu, Emin Gemcioglu, Emra Kalkan, Osman İnan, Abdulrezzak Yilmaz, Bagdagul Güler, Esra Çopuroğlu, İşil Turan, Derya Gökmen, Serhat Hayme, and Aziz Ahmet Surel
- Subjects
General Medicine - Abstract
BackgroundThe aim of the study is to assess the effect of chronic lung disease on mortality in patients hospitalized with the diagnosis of prevariant COVID-19 Pneumonia compared to patients without chronic lung disease.Research design and methodsA cohort of 1,549 patients admitted to the pandemic clinic with a COVID-19 Pneumonia diagnosis was analyzed. Group 1 and Group 2 were compared in terms of the treatment they received, admission to intensive care, mortality and follow-up parameters.ResultsThe patient group with COVID-19 and lung disease consisted of 231 participants (14.91%) (Group 1). The patient group with COVID-19 but without lung disease had 1,318 participants (85.19%). Group 1 cases were found to receive more oxygen therapy and mechanical ventilation than Group 2 cases (p ≤ 0.001), Following univariate and multiple logistic regression analyses, it was determined that patients with chronic lung disease had a 25.76% higher mortality risk [OR: 25.763, 95% CI (Lower-Upper) (2.445–271.465), p = 0.007].ConclusionIt was found that chronic lung disease contributed significantly to mortality in this study. Among chronic lung diseases, Chronic Obstructive Pulmonary Disease (COPD), lung cancer and interstitial lung diseases (ILDs) were shown to be more effective than other chronic lung diseases in patients with prevariant COVİD-19 population.
- Published
- 2022